CJC-1295 DAC Research Guide (Preclinical Overview)
This CJC-1295 DAC research guide provides laboratory investigators with a rigorous technical analysis of the synthetic growth hormone-releasing hormone (GHRH) analog. Designed exclusively for preclinical evaluation, this document details the bioconjugation mechanisms, endocrine signaling dynamics, tissue repair potential, and analytical verification standards required for robust in vitro and animal research protocols.
Quick answer
This CJC-1295 DAC research guide provides laboratory investigators with a rigorous technical analysis of the synthetic growth hormone-releasing hormone (GHRH) analog. Designed exclusively for preclinical evaluation, this document details the bioconjugation mechanisms, endocrine signaling dynamics, tissue repair potential, and analytical verification standards required for robust in vitro and animal research protocols.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) with Drug Affinity Complex (DAC) is a tetrasubstituted 29-amino acid peptide derivative of growth hormone-releasing hormone (GHRH 1-29).
- At the cellular level, [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor (GPCR) predominantly expressed on the somatotroph cells of the anterior pituitary gland.
- The primary differentiator of [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC relative to unmodified GHRH fragments is its extended biological half-life.
- The sustained stimulation of pituitary somatotrophs by [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC leads to a pronounced increase in hepatic IGF-1 synthesis.
Introduction and Structural Chemistry of CJC-1295 DAC
CJC-1295 with Drug Affinity Complex (DAC) is a tetrasubstituted 29-amino acid peptide derivative of growth hormone-releasing hormone (GHRH 1-29). Native GHRH exhibits a rapid biological half-life in mammalian circulation, primarily due to enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) between the alanine and aspartic acid residues at positions 2 and 3. To overcome these kinetic limitations in preclinical evaluation, molecular bioengineers introduced specific amino acid substitutions—specifically D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—along with a reactive Lys(maleimidopropionyl) linker attached to the C-terminus.
The inclusion of the maleimidopropionyl group enables bioconjugation through a covalent nucleophilic addition reaction with free thiol groups present on circulating endogenous serum albumin (specifically the Cys34 residue). This bioconjugation technique significantly alters the pharmacokinetic profile of the peptide without compromising its binding affinity for the growth hormone-releasing hormone receptor (GHRHR). Laboratory investigators utilizing CJC-1295 DAC in experimental models study how this structural stabilization shields the molecule from clearance mechanisms, allowing sustained ligand-receptor interactions over extended baseline intervals.
When designing protocols within growth hormone secretagogues research, understanding the distinct chemical modification of the DAC moiety is vital. High-purity reference materials synthesized in USA-based facilities ensure that the maleimide group remains intact and unreacted prior to introduction into assay media or animal models, safeguarding experimental reproducibility.
Mechanism of Action: GHRH Receptor Binding and Signaling Cascades
At the cellular level, CJC-1295 DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor (GPCR) predominantly expressed on the somatotroph cells of the anterior pituitary gland. Activation of GHRHR initiates a classic signal transduction cascade wherein the Gαs subunit activates adenylyl cyclase, driving an intracellular accumulation of cyclic adenosine monophosphate (cAMP). High cAMP concentrations activate protein kinase A (PKA), leading to the phosphorylation of cAMP response element-binding protein (CREB) and subsequent transcription of the growth hormone (GH) gene.
Simultaneously, the PKA pathway triggers the opening of L-type voltage-gated calcium channels, promoting extracellular calcium influx that prompts exocytosis of stored growth hormone secretory granules. Preclinical studies suggest that because CJC-1295 DAC remains bound to albumin in circulation, it delivers a continuous, low-amplitude signal to somatotroph receptors rather than a sharp, transient surge.
This steady signaling mechanism contrasts with endogenous GHRH dynamics, allowing researchers to evaluate continuous downstream stimulation within ghrh analogs research. The compound's structural integrity ensures high receptor selectivity, preventing non-specific cross-reactivity with adjacent pituitary GPCRs, such as the corticotropin-releasing factor or gonadotropin-releasing hormone receptors.
Pharmacokinetics and Albumin Bioconjugation Dynamics
The primary differentiator of CJC-1295 DAC relative to unmodified GHRH fragments is its extended biological half-life. In vitro binding assays demonstrate that the C-terminal maleimide group forms a stable thioether bond with serum albumin within minutes of exposure to biological fluids. Because serum albumin possesses an extended half-life due to neonatal Fc receptor (FcRn) recycling mechanisms, the bound CJC-1295 DAC complex is protected from both enzymatic degradation and renal filtration.
In animal models, including rodent and non-human primate studies, the functional half-life of CJC-1295 DAC has been observed to extend up to 6 to 8 days, compared to the 5 to 10 minute half-life of native GHRH (1-29). This prolonged systemic persistence maintains baseline elevations in total systemic growth hormone and downstream insulin-like growth factor 1 (IGF-1) concentrations without requiring frequent administration schedules in longitudinal trial protocols.
Researchers evaluating pharmacokinetics in laboratory animals utilize analytical methods such as mass spectrometry and liquid chromatography to track the distribution of both free and albumin-bound peptide fractions over time. Obtaining reference materials with verified high purity and precise conjugation capacity from our research peptides hub is critical for preventing uncoupled side reactions during binding kinetics research.
Downstream Endocrine Pathways: Sustained GH and IGF-1 Expression
The sustained stimulation of pituitary somatotrophs by CJC-1295 DAC leads to a pronounced increase in hepatic IGF-1 synthesis. Systemic growth hormone released into circulation binds to GH receptors on hepatocytes, activating the JAK2/STAT5b signaling pathway. STAT5b dimerization and nuclear translocation drive the transcription of the IGF-1 gene, as well as its key binding proteins, such as IGFBP-3 and the acid-labile subunit (ALS).
Preclinical data indicate that while native GHRH generates pulsatile peaks in GH secretion that return rapidly to baseline, CJC-1295 DAC elevates baseline GH secretion while preserving underlying endogenous pulsatility to a degree dependent on dosage and model parameters. The secondary elevation of circulating IGF-1 remains sustained over several days post-exposure in rodent models.
This long-acting endocrine response makes CJC-1295 DAC a standard reference compound for investigating systemic metabolic regulation, nitrogen retention, and cellular growth pathways. Investigating these biochemical dynamics provides critical insights into endocrine control mechanisms and physiological negative-feedback loops involving somatostatin.
Preclinical Applications in Tissue Repair and Cellular Regeneration
A central focus of research utilizing CJC-1295 DAC revolves around tissue repair, cellular regeneration, and extracellular matrix remodeling. Both GH and IGF-1 exhibit direct trophic effects on diverse tissue types, including skeletal muscle, articular cartilage, bone, and vascular endothelium. In vitro assays evaluating connective tissue fibroblasts demonstrate that elevated IGF-1 concentrations upregulate collagen type I and type III transcription, accelerating cellular migration across wound assays.
In animal models of musculoskeletal injury, preclinical studies suggest that sustained GHRHR activation enhances satellite cell activation, myoblast proliferation, and protein synthesis rates within damaged muscle fibers. Furthermore, in rodent models of focal ischemia and cutaneous wound healing, continuous exposure to elevated IGF-1 signaling correlates with reduced apoptosis rates, enhanced angiogenesis, and accelerated re-epithelialization.
Investigators exploring these tissue repair mechanisms often couple GHRH agonists with other research compounds to examine potential synergistic pathways in cellular recovery models. Research laboratories can access specialized materials through our wholesale lab account portal to support large-cohort cellular regeneration projects.
Comparative Analysis: CJC-1295 DAC vs. CJC-1295 No DAC, Sermorelin, and Tesamorelin
To establish appropriate experimental designs, researchers must understand the key distinctions between CJC-1295 DAC and related GHRH derivatives. The primary variance lies in pharmacokinetic duration and structural modification. While CJC-1295 DAC incorporates the reactive maleimide linker for albumin bioconjugation, CJC-1295 No DAC lacks this group, resulting in a substantially shorter half-life (approximately 30 minutes in rodent models) that creates acute, transient GH pulses rather than sustained baseline shifts.
Similarly, Sermorelin represents the unmodified core sequence of endogenous GHRH (GHRH 1-29 amide). Lacking the protective D-Ala substitutions and albumin-binding complex, Sermorelin is rapidly cleared by DPP-IV enzymes, offering a transient pulse profile ideal for baseline pituitary responsiveness testing. On the other hand, Tesamorelin features a trans-3-hexenoic acid modification attached to the N-terminus of GHRH 1-44, optimized specifically for metabolic and lipodystrophy models with intermediate stability compared to native GHRH.
In cross-comparison research protocols, investigators often co-evaluate CJC-1295 DAC alongside selective ghrelin receptor agonists such as Ipamorelin to observe dual-receptor signaling dynamics. While GHRH analogs activate the Gαs/cAMP pathway, growth hormone secretagogue receptor (GHSR-1a) agonists operate through the Gαq/phospholipase C pathway, offering a complementary mechanism for studying synergistic pituitary secretagogue activity.
Model Systems and In Vitro / In Vivo Assay Protocols
Evaluating CJC-1295 DAC across experimental platforms requires precise model selection. In vitro methodologies routinely employ primary anterior pituitary cell cultures or immortalized GH3 cell lines to quantify intracellular cAMP accumulation, calcium flux, and GH gene transcript levels following peptide exposure. These assays permit strict isolation of GHRHR-mediated signaling from systemic feedback control.
In vivo methodologies typically utilize rodent models (such as C57BL/6 mice or Sprague-Dawley rats) to map systemic endocrine cascades. Researchers evaluate serum parameter kinetics by collecting serial blood samples over multi-day periods to measure GH and IGF-1 titers via high-sensitivity ELISA assays. Tissue histology, Western blotting for phosphorylated STAT5b, and qPCR for collagen expression are standard techniques applied post-study to assess peripheral tissue adaptation.
All protocols involving live animal models must adhere strictly to Institutional Animal Care and Use Committee (IACUC) guidelines and institutional oversight. CJC-1295 DAC supplied by PX1 Research is strictly designated for laboratory research use only and must never be introduced into clinical or human research protocols.
Analytical Purity Standards: HPLC, Mass Spectrometry, and Endotoxin Limits
In preclinical peptide research, chemical purity and batch consistency directly govern data reliability. Minor peptide fragments, truncated sequences, or residual cleavage reagents can cause off-target cellular toxicity or unpredictable receptor interactions. PX1 Research subjects every lot of CJC-1295 DAC to rigorous analytical verification within an ISO 17025 accredited laboratory.
Purity assessment requires Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring that the primary peak achieves a purity threshold of ≥98.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) is simultaneously performed to verify the exact molecular weight (3647.95 Da) and confirm the structural presence of the maleimidopropionyl linker. This prevents the usage of degraded or non-functional bioconjugate reagents in binding studies.
Equally critical is strict control of bacterial endotoxins. Lipopolysaccharides (LPS) from Gram-negative bacteria can induce profound inflammatory responses in cell cultures and animal models, confounding cytokine and tissue repair assays. PX1 Research performs quantitative Chromogenic Recombinant Factor C (rFC) or LAL testing to guarantee endotoxin levels remain below standard analytical thresholds (<0.1 EU/mg), ensuring reliable in vitro and in vivo performance.
Reconstitution, Handling, and Laboratory Storage Protocols
CJC-1295 DAC is supplied as a lyophilized, sterile-filtered powder to preserve structural integrity during transit and storage. Lyophilized vials should be kept in a freezer at -20°C for short-term preservation or -80°C for long-term storage, protected from light exposure to prevent photo-degradation.
When preparing the compound for experimental protocols, researchers should follow strict aseptic techniques. Reconstitution should be performed using sterile Bacteriostatic Water or sterile 0.9% Sodium Chloride injection solution, depending on the requirements of the biological assay. For detailed procedural step-by-step instructions, investigators should reference our comprehensive peptide reconstitution guide.
During reconstitution, the diluent should be introduced gently along the glass wall of the vial, followed by gentle swirling rather than vigorous vortexing, as mechanical agitation can induce peptide shear stress and aggregation. Once reconstituted, liquid solutions should be stored at 2°C to 8°C and utilized within a strict experimental timeframe to prevent loss of bioconjugation reactivity.
Frequently Asked Questions
What is the specific role of the DAC group in CJC-1295 DAC research?
The Drug Affinity Complex (DAC) consists of a maleimidopropionyl linker attached to the C-terminus of the peptide. In biological environments, it forms a covalent bond with free cysteine residues on circulating serum albumin, extending the peptide's biological half-life and preventing enzymatic degradation by DPP-IV.
How does CJC-1295 DAC differ from CJC-1295 No DAC in laboratory settings?
CJC-1295 DAC contains the maleimide bioconjugation group that binds albumin, extending its functional half-life to several days in animal models. CJC-1295 No DAC lacks this group, resulting in a short half-life (~30 minutes) and producing transient, acute GH pulses rather than sustained elevations.
What analytical methods are used to verify the purity of PX1 Research peptides?
PX1 Research utilizes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify ≥98% chemical purity and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular weight. Every lot is also tested for bacterial endotoxins and accompanied by a Certificate of Analysis (COA).
What are the recommended storage conditions for lyophilized CJC-1295 DAC?
Lyophilized CJC-1295 DAC should be stored at -20°C for short-term requirements or -80°C for long-term stability, kept away from light and moisture. Upon reconstitution, solutions must be kept refrigerated at 2°C to 8°C.
Can CJC-1295 DAC be reconstituted in standard phosphate-buffered saline (PBS)?
Yes, CJC-1295 DAC can be reconstituted in sterile PBS or Bacteriostatic Water depending on assay requirements. However, researchers should ensure the pH remains neutral (7.2–7.4) to maintain the chemical stability of the maleimide functional group prior to bio-introduction.
What endotoxin standards are enforced for PX1 Research compounds?
All research peptides provided by PX1 Research undergo rigorous endotoxin testing via LAL or rFC assays, guaranteeing endotoxin levels are strictly below <0.1 EU/mg to prevent inflammatory artifact interference in cellular and animal assays.
What receptor target does CJC-1295 DAC bind to in cell models?
CJC-1295 DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a G-protein-coupled receptor located on pituitary somatotrophs, activating the Gαs/cAMP/PKA signaling cascade.
Where are PX1 Research peptides synthesized and shipped from?
All PX1 Research compounds are synthesized in state-of-the-art USA facilities operating under ISO 17025 and GMP-compliant standards, and shipped directly from fulfillment centers located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.